The UV research groups (GIUV) are regulated in the 1st chapter of the Regulation ACGUV48/2013, which explains the procedure for creating new research structures. They are basic research and organizational structures that result from the voluntary association of researchers that share objectives, facilities, resources and common lines of research. These researchers are also committed to the consolidation and stability of their activity, work in groups and the capability to achieve a sustainable funding.
The research groups included in the previously mentioned Regulation are registered in the Register of Research Structures of the Universitat de València (REIUV), managed by the Office of the Vice-principal for Research. The basic information of these organisms can be found in this website.
Participants
Data related to research groups featured in various information dissemination channels shall not, under any circumstances, imply a statement or commitment regarding the employment or academic affiliation of individuals associated with the Universitat de València. Their inclusion is solely the responsibility of the group directors. Updates will be made upon request from interested parties.
- Registered groups in the Register of Research Structures of the Universitat de València - (REIUV)
Reference of the Group:
Description of research activity: At the beginning, our group was dedicated to the study and characterisation of gastrointestinal disorders related to acid production and motility, becoming an international reference group in this field due to the large number of high-level publications in the area of basic or experimental pharmacology. New applications for the study of drug effects, such as genetics or molecular biology, have led to a broadening of the topics to be studied. The most important characteristic of our group from a research point of view is the desire for our different lines of research to be focused on the study of physiological and pathological processes with a broad clinical impact. That is why our lines of research address diseases of particular relevance in today's society: Crohn's disease, NSAID gastroenteropathy, AIDS, diabetes and obesity. Since its foundation in 2007, our group has been part of the Centro de Investigación Biomédica en Red: Liver and Digestive Diseases (CIBERehd), whose function is to promote research of excellence at both clinical and basic levels. In addition, we have been recognised by the Valencian Government as a group of excellence within the PROMETEO 2010 call. Our...At the beginning, our group was dedicated to the study and characterisation of gastrointestinal disorders related to acid production and motility, becoming an international reference group in this field due to the large number of high-level publications in the area of basic or experimental pharmacology. New applications for the study of drug effects, such as genetics or molecular biology, have led to a broadening of the topics to be studied. The most important characteristic of our group from a research point of view is the desire for our different lines of research to be focused on the study of physiological and pathological processes with a broad clinical impact. That is why our lines of research address diseases of particular relevance in today's society: Crohn's disease, NSAID gastroenteropathy, AIDS, diabetes and obesity. Since its foundation in 2007, our group has been part of the Centro de Investigación Biomédica en Red: Liver and Digestive Diseases (CIBERehd), whose function is to promote research of excellence at both clinical and basic levels. In addition, we have been recognised by the Valencian Government as a group of excellence within the PROMETEO 2010 call. Our group has published more than 200 articles and reviews in international journals including, among others, Gastroenterology, Hepatology, PNAS, Circulation, Immunity, Circulation Research, British Journal of Pharmacology and Trends in Pharmacological Sciences.[Read more][Hide]
Web:
Scientific-technical goals: - Esclarecer los mecanismos fisiopatologicos de las enfermedades cronicas mencionadas anteriormente y optimizar el tratamiento de las mismas.
Research lines: - Modulation of autophagy in epithelial cells by macrophages: relevance in Crohn¿s Disease and in non-steroidal anti-inflammatory drug-induced gastroent.We study the mechanisms that regulate gastrointestinal mucosal recovery in chronic inflammatory pathologies (e. g. IBD), in particular how macrophages, cells of the innate immune system that accumulate in the mucosa of patients with this pathology, modulate these mechanisms.
- Study of the cellular and molecular mechanisms involved in the vascular toxicity induced by antiretroviral therapy..We study the mechanisms responsible for the vascular toxicity described for some antiretroviral drugs. We have analysed the effect of the most commonly used antiretroviral drugs on leukocyte-endothelium interaction as a first step in the development of vascular pathologies.
- Characterisation of cellular mechanisms of toxicity induced by antiretroviral drugs..We study the mechanisms responsible for the toxicity of antiretroviral therapy in different organs and tissues, with special emphasis on three of the main adverse effects associated with this treatment: liver toxicity, metabolic alterations and neurotoxicity.
- Mitochondrial-endothelial dysfunction, reticulum stress and autophagy in type 2 diabetes: physiolopathological and therapeutic implications..We studied type 2 diabetes and mitochondrial dysfunction, having shown that it correlates with the development of silent ischaemic heart disease. We have also shown that high levels of myeloperoxidase correlate with the development of diabetic nephropathy in type 2 diabetes.
Group members:
CNAE:
Associated structure:
Keywords: - inflamación, función barrera-epitelial, enfermedad de Chron, colitis ulcerosa, inmunidad innata
- Antirretroviral, toxicidad vascular, interacción leucocito-endotelio, plaqueta, moléculas de adhesión.
- hepatotoxicidad, antirretrovirales, mitocondria, VIH, neurotoxicidad, bioenergética
- Diabetes tipo 2, mitocondria, endotelio, enfermedad cardiometabólica, humanos
